These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32787376)

  • 1. Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study.
    Chen HH; Hsieh MC; Ho CW; Chen CC; Hsu SP; Lin CL; Kao CH
    Ann Palliat Med; 2020 Sep; 9(5):2817-2825. PubMed ID: 32787376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor treatment could decrease
    Chen HH; Chen CC; Ho CW; Hsieh MC; Hsu SP; Lin CL; Kao CH
    Postgrad Med; 2020 Nov; 132(8):714-719. PubMed ID: 32633173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
    Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
    J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Seong JM; Yee J; Gwak HS
    Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
    Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
    Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients.
    Li SY; Chen HH; Lai CC; Lin CL; Kao CH
    QJM; 2020 Mar; 113(3):181-185. PubMed ID: 31584671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
    Wang J; Wu HY; Chien KL
    Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
    Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
    Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus.
    Wang CY; Liao KM; Wang YH; Chen KH; Chuang S; Liu CJ; Shu CC; Wang HC
    J Infect Public Health; 2023 Nov; 16(11):1709-1715. PubMed ID: 37729686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
    Charoenngam N; Rittiphairoj T; Ponvilawan B; Ungprasert P
    Diabetes Metab Syndr; 2021; 15(1):249-255. PubMed ID: 33465685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
    Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
    J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.
    Wvan der Zanden R; de Vries F; Lalmohamed A; Driessen JH; de Boer A; Rohde G; Neef C; den Heijer C
    PLoS One; 2015; 10(10):e0139367. PubMed ID: 26468883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
    Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB
    Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.
    Roberto G; Barone-Adesi F; Giorgianni F; Pizzimenti V; Ferrajolo C; Tari M; Bartolini C; Da Cas R; Maggini M; Spila-Alegiani S; Francesconi P; Trifirò G; Poluzzi E; Baccetti F; Gini R
    BMC Endocr Disord; 2019 Feb; 19(1):18. PubMed ID: 30732592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.